<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To study factor V Leiden, prothrombin (G1691A), 5, 10-<z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> reductase (MTHFR, C677T) mutations in patients with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) and cerebrovascular disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: We studied 44 patients (38 female, 6 male, mean age 41.6 +/- 11.6 years) with PAPS and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Detection of mutations was carried out using polymerase chain reaction </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0584984" disease_type="Disease or Syndrome" abbrv="">Heterozygous factor V Leiden mutation</z:e> was found in 11% patients, heterozygous prothrombin mutation--in 9%, heterozygous and homozygous MTHFR mutation--in 50% and 9%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The severity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, frequency of clinical manifestations related to non-cerebral arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> did not differ between the patients with and without mutations or there was a tendency to less frequent occurrence of these manifestations in patients with mutations </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with <z:e sem="disease" ids="C0584984" disease_type="Disease or Syndrome" abbrv="">heterozygous factor V Leiden mutation</z:e>, heterozygous prothrombin mutation or homozygous MTHFR mutation less frequently developed recurrent <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> than patients without these mutations (8% versus 44%, p &lt; 0.02) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: It is suggested that mutations studied do not play a significant role in development of cerebral and systemic <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients with PAPS </plain></SENT>
<SENT sid="7" pm="."><plain>The leading role belongs to <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) </plain></SENT>
<SENT sid="8" pm="."><plain>Sometimes these mutations may protect from thrombogenic aPL action </plain></SENT>
<SENT sid="9" pm="."><plain>This could underlie less frequent development of recurrent <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in patients with mutation </plain></SENT>
</text></document>